NOVEOSTM and ImmunoCAPTM have similar performances for diagnosing food allergies.

Benjamin Trouche-Estival,Joana Vitte,Audrey Martin-Blondel,Marine Michelet,Vianney Gruzelle,Alain Didier,Laurent Guilleminault,Claire Mailhol,Silvia Martinez Rivera,Anaïs De Lima Correia,Camille Taurus,Antoine Blancher,Julien Goret,Caroline Klingebiel,Pol André Apoil
DOI: https://doi.org/10.1016/j.jaip.2024.02.037
IF: 11.022
2024-03-08
The Journal of Allergy and Clinical Immunology In Practice
Abstract:Background The clinical interest of newly available platforms for specific IgE measurement must be evaluated. However, data are lacking for NOVEOSTM (Hycor), in particular for food allergens. Objective We compared technical and clinical performance of two platforms (ImmunoCAPTM and NOVEOSTM) for the measurement of specific IgE to 10 food allergens. Methods Sera from 289 clinically-characterized patients were tested for IgE specific for six food allergen extracts (egg white, cow's milk, peanut, hazelnut, fish, shrimp) and four molecular allergens (Gal d 1, Bos d 8, Ara h 2, Cor a 14). Specific IgE measurements were carried out using ImmunoCAPTM and NOVEOSTM methods. Food allergy diagnosis was established according to international guidelines. Results A strong correlation (rho>0.9) was present between the two platforms, while specific IgE concentrations measured with NOVEOSTM were consistently lower (mean -15%) than with ImmunoCAPTM. NOVEOSTM and ImmunoCAPTM provided similar overall odds ratios and relative risks for food allergy diagnosis, with both allergen extracts and molecular allergens. When all 10 allergens were considered, NOVEOSTM provided better ROC curves (p=0.04). Finally, we found that the most discordant results were observed with hazelnut and peanut extracts, and were related to cross-reactive carbohydrate determinants on these two ImmunoCAPTM. Conclusions Specific IgE determination by either ImmunoCAPTM or NOVEOSTM (odd-ratios of allergy were 25.1 or 33.0, respectively) is highly informative on the risk of allergy in the selected population. The NOVEOSTM platform presents the advantage of being less affected by unwanted reactivity due to carbohydrate determinants-specific IgE, while requiring a ten-fold lower test sample volume.
immunology,allergy
What problem does this paper attempt to address?